A new mouse model of poorly differentiated thyroid carcinoma and its implications for human disease. by Bongiovanni, M. & Sykiotis, G.P.
© Gland Surgery. All rights reserved.   Gland Surg 2020;9(2):481-484 | http://dx.doi.org/10.21037/gs.2020.01.02
Among the primary malignancies of the thyroid gland, 
the vast majority is represented by differentiated thyroid 
carcinoma (DTC), which comprises papillary thyroid 
carcinoma (PTC), follicular thyroid carcinoma (FTC) and 
oncocytic or Hürthle cell thyroid carcinoma (HTC). In 
most cases, these carcinomas are of a rather indolent nature 
and are treated very effectively with surgery, followed 
by radioactive iodine (RAI) in selected cases. Most of 
the disease-related mortality among patients with DTC 
concerns tumors that are RAI-refractory, which are rare; 
thus, the overall mortality associated with DTC is quite 
low. At the other end of the spectrum of primary thyroid 
malignancies lies anaplastic thyroid carcinoma (ATC), an 
aggressive and rapidly progressive cancer with a very high 
mortality rate. Because ATC does not express markers of 
thyroid differentiation, it is also termed undifferentiated 
thyroid carcinoma (UTC). This lack/loss of differentiation 
has important therapeutic and prognostic implications: 
because ATC cells do not express functional sodium-
iodide symporter (NIS), RAI treatment has no place in the 
management of these tumors.
Between these two extremes, DTC and ATC, lies a 
group of tumors classified as poorly differentiated thyroid 
carcinoma (PDTC). These tumors do not meet the 
diagnostic criteria of ATC because they retain features of 
thyroid differentiation, albeit to varying degrees. Despite 
this variability, the histological diagnosis of PDTC does 
not pose problems, as its recognition is based on the so-
called Turin criteria (1), which have been endorsed also by 
the World Health Organization classification of tumors of 
endocrine organs (2). Briefly, PDTC is defined as a thyroid 
malignant neoplasm (with extensive capsular and vascular 
invasion) that shows necrosis and a high mitotic activity. 
PDTC and DTC can coexist in the same patient, which is 
important to recognize because studies have shown that a 
PDTC component >10% in an otherwise DTC can have 
a negative impact on prognosis (3). PDTC can also be a 
precursor of ATC, and the two tumor types can also coexist 
in the same patient and they can have various molecular 
alterations in common (4).
In terms of its clinical behavior, PDTC is often, but 
not always, an aggressive tumor, including being RAI-
refractory; thus, the overall prognosis of PDTC is 
intermediate between the favorable prognosis of DTC and 
the pessimistic prognosis of ATC. However, and in contrast 
to ATC that warrants immediate aggressive treatment, it 
is generally not possible to predict in an individual patient 
with PDTC, at the moment of initial diagnosis, whether the 
tumor will behave aggressively or whether it can be cured 
by surgery and RAI. Thus, the initial treatment of most 
patients with PDTC is similar to that of “high-risk” patients 
with DTC (i.e., total thyroidectomy and RAI); this is 
sufficient for many patients, yet for others it may represent 
a loss of precious time. Therefore, further research is 
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warranted to understand the pathogenesis and tumor 
evolution of PDTC, including the mechanisms involved in 
the maintenance or loss of differentiated features (e.g., NIS 
expression and functionality) and their clinical (e.g., RAI 
uptake) and prognostic correlates (RAI-sensitive vs. RAI-
refractory nature).
A recent study by the group of Yuri Nikiforov published 
in the October 2019 issue of Thyroid aimed to address some 
of these questions using a mouse model of PDTC (5). 
In previous work, the same group had created mice with 
targeted overexpression in thyroid follicular cells [using 
a promoter of the gene encoding thyroglobulin (Tg)] of 
a STRN-ALK fusion protein, and had shown that these 
mice develop tumors that meet the histological diagnostic 
criteria of PDTC (6). ALK (anaplastic lymphoma kinase) 
is a receptor tyrosine kinase expressed in various tissues; 
the ALK gene is a known oncogene that is activated by 
chromosomal translocations generating ALK fusion genes. 
Among the various early driver mutations encountered 
in thyroid carcinomas (primarily BRAF and RAS point 
mutations), ALK fusions are found in small subsets of 
PTC (1.6%), PDTC (9%) and ATC (4%) (7). In thyroid 
carcinomas, the most frequent translocation partner is the 
STRN gene that encodes striatin, a calmodulin-dependent 
scaffolding protein (8). STRN-ALK fusion proteins lead to 
constitutive activation of ALK signaling via dimerization 
mediated by the coiled-coil domain of striatin; this induces 
kinase-dependent, thyroid-stimulating hormone (TSH)-
independent proliferation of thyroid cells (7).
Within a thyroid tissue proliferating under the influence 
of an early genetic driver event, the occurrence of late 
genetic driver events, such as loss of the anti-oncogene p53 
(the so-called “guardian of the genome”) (9), can trigger 
a rapid and more aggressive carcinogenic process that can 
culminate in PDTC and/or ATC (3). Therefore, to better 
account for the contribution of late genetic driver events, in 
the present study Nikitski et al. expanded on their previously 
characterized STRN-ALK fusion-driven PDTC model by 
deleting the p53 gene (via Cre-recombinase also expressed 
by the same Tg promoter) specifically in the same thyroid 
follicular cells that overexpressed the STRN-ALK fusion 
transgene (5). A subset of ALK-overexpressing, homozygous 
p53-deleted mice were also treated with antithyroid 
medications (thyroid hormone synthesis inhibitors and 
perchlorate) to increase the serum levels of TSH (considered 
to promote thyroid cell growth and proliferation) and thus 
test the effect that this further stimulation might have on 
tumor development.
Using a special micro-instrument, the mice were 
monitored non-invasively by thyroid ultrasound for the 
development of thyroid tumors, which appeared from 
the age of 7 months on normal diet or 5 months under 
goitrogen treatment. Some of the tumors that were 
followed by ultrasound in these mice started to grow more 
rapidly; after sacrifice of the animals, these were shown to 
be foci of PDTC growing next to foci of PTC, supporting 
the concept that PDTC can result from the evolution and 
dedifferentiation of PTC. Indeed, these mice developed 
PTC (most frequently) and PDTC but also ATC (less 
frequently). Different types of thyroid carcinoma could 
be observed in the same mouse, the most frequent being 
the combination of PTC and PDTC. The most dominant 
type was PDTC, occupying the larger part of the thyroid 
parenchyma. In mice treated with goitrogen, not only was 
the time to tumor development shorter, but the frequency 
of tumor development was also higher and the distribution 
of  the observed tumor types was shifted towards 
dedifferentiation. Irrespective of goitrogen treatment, 
the tumors observed showed aggressive features such as 
extrathyroidal extension, invasion of trachea and blood 
vessels as well as frequent lung metastases.
Histologically, the PDTC tumors developed in these 
mice fulfilled the aforementioned Turin diagnostic criteria. 
However, an interesting observation was that these PDTC 
tumors could be classified into two histological subtypes 
according to cell morphology: The PDTC1 subtype 
comprised cells with a substantial amount of cytoplasm 
and small nuclei with dense, evenly distributed chromatin 
(Figure 1); these features generally resemble those of DTC 
cells. On the other hand, PDTC2 tumors comprised cells 
with less cytoplasm and larger, vesicular nuclei that had 
prominent and often multiple nucleoli (Figure 1); these 
features bear no resemblance to those of DTC cells. Most 
mice developed either PDTC1 or PDTC2 tumors, whereas 
some mice developed both PDTC1 and PDTC2 tumors, 
located next to each other; in those cases, the correlation 
between the ultrasonographic follow-up of the mice and 
the histopathology results showed that PDTC1 tumors 
developed earlier than PDTC2 tumors in the same mouse.
The two types of PDTC distinguished based on 
morphology turned out to be distinct also in terms of 
the expression of genes related to follicular thyroid cell 
differentiation. Specifically, the expression of thyroid-
specific genes was analyzed by RNA sequencing and 
the abundance of thyroid-specific proteins was studied 
by immunohistochemistry. These analyses showed that 
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PDTC1 tumors retained immunoreactivity of thyroid 
differentiation markers like Tg and of general epithelial 
markers like E-cadherin, whereas these proteins were 
undetectable in PDTC2 tumors. Similarly, at the mRNA 
level, PDTC1 tumors showed higher expression levels of 
the thyroid-specific genes Tg, Nis, thyroid peroxidase (Tpo) 
and dual-oxidase 2 (Duox2) as compared to PDTC2 tumors.
Based on these novel findings, the authors draw 
interesting conclusions regarding the pathogenesis of 
PDTC associated with STRN-ALK fusion and p53 loss. 
The model shown in Figure 1 summarizes the putative 
tumorigenesis, progression and dedifferentiation process 
in these mice, with the main pathway being from PTC 
to PDTC, to then possibly also ATC. Another important 
conclusion is that two distinct types of PDTC can develop, 
with PDTC2 being more advanced and less differentiated, 
both in terms of cell morphology and in terms of thyroid-
specific gene expression. Both types can derive from PTC, 
or, less likely, from normal thyroid tissue; progression from 
PDTC1 to PDTC2 is possible, and both types may also 
progress to ATC (Figure 1).
The authors also speculate that the existence of two 
subtypes of PDTC, a less aggressive one that retains 
differentiation markers and a more aggressive one that has 
lost them, might be related to the corresponding variable 
clinical behavior of PDTC in humans. For example, 
approximately half of PDTC tumors in patients retain 
the ability to concentrate RAI (10). It might thus be that 
these tumors are similar, in terms of histology and gene 
expression, to the PDTC1 tumors observed in mice in the 
present study, whereas those that are RAI-refractory might 
be similar to PDTC2 tumors. However, it is currently 
unknown whether distinct subtypes of PDTC exist in 
humans, and this issue certainly warrants clarification in 
further studies. Also, as the authors acknowledge, it will 
be important to test whether the higher Nis expression 
observed in PDTC1 tumors in mice correlates with ability 
to concentrate RAI, as this question was not addressed in 
the present study (5).
This elegant study has several strengths, including the 
genetic introduction of clinically-relevant mutations, the 
non-invasive monitoring of the animals, the investigation 
of the contribution of goitrogen, and the detailed 
characterization of tumor types within and between 
animals, among others. On the other hand, it also has 
some limitations that merit consideration. One such 
limitation, acknowledged by the authors, is the use of a 
Tg promoter to drive the expression of the STRN-ALK 
fusion transgene as well as to trigger the recombination 
events deleting p53. Because Tg expression decreases with 
tumor dedifferentiation, this can have confounding effects 
on the degree of STRN-ALK expression and its associated 
phenotypes. For example, it may explain the relatively low 
penetrance of ATC in these mice. It also makes these mice 
unsuitable as a model to test the therapeutic effects of ALK 
inhibitors. The authors state that they plan to address this 
issue by using a doxycycline-inducible promoter in the place 
of the Tg promoter (5).
There are some additional limitations that are not 
discussed by the authors but may have clinical implications: 
(I) the model combined an early genetic event in PDTC 
evolution (i.e., the STRN-ALK fusion) with a late genetic 
event (loss of p53), and both of these events were triggered 
simultaneously and from early developmental stages 
using the Tg promoter. Thus, the stepwise process of 
tumor development with sequential early and late events 
was not recapitulated in a strict manner. However, this is 
understandable for the present study, given the complexity 
of genetic and pharmacological manipulations that would 
be necessary to mimic more closely the sequence and 
timing of human PDTC-relevant events; (II) also with 
reference to the genetic events modeled, as mentioned 
above, ALK fusions are found only in a minority of PTC, 
PDTC and ATC in humans (7). Thus, the clinical relevance 
of the findings for the vast majority of PDTC that do not 
harbor ALK fusions remains unknown. In that regard, 
the envisioned clinicopathological studies to investigate 
whether PDTC subtypes corresponding to PDTC1 and 
PDTC2 exist in humans should ideally consider the specific 
mutations that the respective tumors harbor; (III) further 
regarding tumor genetic composition, it is also important to 
note that the present study did not investigate the presence 
Figure 1 Putative scheme of progression and dedifferentiation of 
thyroid cancer in SRTN-ALK;p53 KO mice. Thickness of arrows 
represents number of cases. Figure and legend reproduced from 
the original publication by Nikitski et al. (5), with permission from 
Mary Ann Liebert, Inc.
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of any additional mutations acquired by the PDTC tumors 
that might account for the different cellular behaviors and 
evolution paths between PDTC1 and PDTC2 (Figure 1). 
Since loss of p53 is well-known to lead to genome 
instability, secondary mutational events are expected to 
accumulate during tumor progression, and it would be very 
interesting to map such events by comparing the genetic 
composition of PTC, PDTC1, PDTC2 and ATC tumors 
in these animals. It is possible that the authors, who are 
renowned experts in the genetics of thyroid carcinoma, may 
be currently working to address this question; (IV) lastly, 
the authors do not discuss how the possible existence of two 
distinct types of PDTC with different cell morphology may 
facilitate, or rather, further complicate, the preoperative 
diagnosis of PDTC by fine-needle aspiration biopsy, which 
remains a major challenge (11).
In conclusion, the elegant study by Nikitski et al. 
yields new insights into the pathogenesis of PDTC in a 
genetically defined mouse model (5). It represents a logical 
extension of a previous study by the same group (6), and 
it is expected that it will be followed by mouse and human 
clinicopathological studies to gain further insights with 
potential implications for the corresponding human disease.
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